GlobeNewsWire
19 Nov 2026, 06:00 UTC · 17h ago
Press Release: Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
Impact · against what's priced in
Sanofi receives a modest positive catalyst from the EU approval of VaxRabeo for all age groups. The expanded patient population for both pre- and post-exposure prophylaxis provides a clear path to incremental revenue growth in the EU market starting in 2027.
- SNY+0.30
No priced-in read yet





